Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Belinda Marcus

Undersea and Hyperbaric Medicine Newnan, GA Medical Doctor

NPI 1457440281 CMS profile 21048

2401 Newnan Crossing Blvd E Ste E, Newnan, GA 30265

Open in the dashboard

General payments

$26,192

108 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Belinda Marcus of Newnan, GA is reported in the CMS Open Payments database as having received $26,192 across 108 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Undersea and Hyperbaric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $234 9
2024 General $239 10
2023 General $463 15
2022 General $20,453 54
2021 General $268 8
2020 General $3,053 4
2019 General $1,481 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Belinda Marcus
  • Undersea and Hyperbaric Medicine median
  • Middle half of Undersea and Hyperbaric Medicine
  • National median

In program year 2025, general payments to Belinda Marcus were reported at $234. Among 65 Undersea and Hyperbaric Medicine profiles paid that year, the median was $153 and the middle half received between $68 and $340.

Show as a table
Year Belinda Marcus Undersea and Hyperbaric Medicine median Middle half National median
2019 $1,481 $162 $85–$376 $163
2020 $3,053 $111 $46–$307 $114
2021 $268 $154 $50–$306 $132
2022 $20,453 $122 $40–$378 $149
2023 $463 $145 $52–$410 $160
2024 $239 $146 $80–$316 $164
2025 $234 $153 $68–$340 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bioventus LLC $20,304 47 payments
  2. Kerecis Limited $4,263 5 payments
  3. Misonix Inc $256 3 payments
  4. Philips Electronics North America Corporation $220 3 payments
  5. Organogenesis Inc. $220 8 payments
  6. Smith+Nephew, Inc. $209 7 payments
  7. ConvaTec Inc. $114 6 payments
  8. Cardiva Medical, Inc. $93 1 payment
  9. Hydrofera LLC $53 3 payments
  10. Janssen Pharmaceuticals, Inc $52 3 payments
  11. Other $407 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $15,122 7 payments
  2. Travel and Lodging $4,771 21 payments
  3. Consulting Fee $4,000 2 payments
  4. Food and Beverage $2,299 78 payments
Products named General payments · program years 2019–2025
  1. Kerecis Omega3 Wound $4,221 4 payments
  2. Bonescalpel $184 1 payment
  3. TheraSkin $144 2 payments
  4. Puraply $127 4 payments
  5. GRAFIX $114 3 payments
  6. IGT D Peripheral $112 1 payment
  7. Cardiva VASCADE 6/7F VCS $93 1 payment
  8. (9281) Turbo Elite $86 1 payment
  9. ACTIV.A.C. $55 3 payments
  10. SonicOne Clinic $55 2 payments
  11. Other $1,060 49 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

41

Median for Emergency Medicine: 88

Drug cost

$262

Median for Emergency Medicine: $590

Branded share of claims

0%

Median for Emergency Medicine: 33.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Doxycycline Hyclate Generic 29 $257
Triamcinolone Acetonide Generic 12 $5

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$97,786

Medicare's payments for the services billed

Medicare patients

205

Average age 73

Services billed

1,667

106 women, 99 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Diabetes 56%
Chronic kidney disease 43%
Heart failure 40%
Ischemic heart disease 36%
Atrial fibrillation 27%
Depression 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

108 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Undersea and Hyperbaric Medicine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record